# US 2026/0098065 A1 · Method for attenuating eosinophils-driven inflammation using a composition for mucosal administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098065 A1
- Document ID: US20260098065A1
- Status: Published application
- Kind: A1
- Application number: 19/341,203
- Filed: 2025-09-26
- Published: 2026-04-09
- Earliest claimed: 2024-10-07
- Assignees: Advagene Biopharma Co., Ltd.
- Applicants: Advagene Biopharma Co., Ltd.
- Inventors: Han-Pin KUO; Yu-Shen HSU; Ming-I CHANG; Yi-Shiuh HWANG
- Web page: https://patentgrep.com/patent/US20260098065A1

## CPC

- A61K 38/164: {from bacteria}
- C07K 14/245: Escherichia (G)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides a method for treating a subject having eosinophil-associated inflammation, such as severe asthma, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli labile toxin (LT).

## Claims

### Claim 1

A method for treating a subject with eosinophil-associated inflammation in respiratory tissues and anatomically or immunologically adjacent tissues, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli heat-labile toxin (LT), wherein the composition is administered via a mucosal route.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered via an intranasal route.

### Claim 3 (depends on 1)

The method of claim 1, wherein the eosinophil-associated inflammation comprises asthma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the eosinophil-associated inflammation comprises eosinophilic chronic rhinosinusitis (eCRS).

### Claim 5 (depends on 1)

The method of claim 1, wherein the eosinophil-associated inflammation comprises eosinophilic esophagitis (EoE).

### Claim 6 (depends on 3)

The method of claim 3, wherein the asthma is moderate to severe asthma, determined according to the Global Initiative for Asthma (GINA) 2023.

### Claim 7 (depends on 3)

The method of claim 3, wherein the asthma is moderate to severe asthma determined according to the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report (EPR)-4 2023.

### Claim 8 (depends on 1)

The method of claim 1, wherein the detoxified Escherichia coli heat-labile toxin (LT) is LTh(αK).

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is administered one or more times.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is administered alone.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is administered in combination with other treatments.

### Claim 12 (depends on 1)

The method of claim 1, wherein administration of the composition induces Type I interferon (IFN) production.

### Claim 13 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the blood eosinophil counts.

### Claim 14 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the sputum eosinophil counts.

### Claim 15 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the fractional exhaled nitric oxide (FeNO).

### Claim 16 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the sputum eosinophilic cationic protein (ECP).

### Claim 17 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the blood IL-4 cytokine.

### Claim 18 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the sputum IL-4 cytokine.

### Claim 19 (depends on 1)

The method of claim 1, wherein administration of the composition reduces the blood IL-5 cytokine.

### Claim 20 (depends on 1)

The method of claim 1, wherein administration of the composition enhances the Forced Expiratory Volume in 1 second (FEV1).
